Converd’s clinical trial of using oncolytic virus in combination with immunotherapy for gastrointestinal cancers
Column:Company News Time:2018-04-30
Converd has initiated a phase I/II clinical trial: A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer agent (A01) with Immune Cells (IC01) in patients with Advanced Gastrointestinal Cancer.

      Converd has initiated a phase I/II clinical trial:  A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer agent (A01) with Immune Cells (IC01) in patients with Advanced Gastrointestinal Cancer. This trial is designed to assess the safety, tolerability and efficacy of a novel combination therapy in patients with an advanced stage of gastrointestinal cancers. The trial is currently conducted in the Jiaxing 2nd Hospital. This trial is registered in the ClinicalTrials.gov. For more details, use the link:https://clinicaltrials.gov/ct2/show/NCT03472352?term=NCT03472352&rank=1